Hematology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Acute myeloid leukaemia"

Interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp ( Darbepoetin alfa ) administered every three weeks to treat anemia in patients with a bone marrow disorder known as myelodys ...

The results from AZA-001 are published in The Lancet Oncology. The data indicate that Vidaza ( Azacitidine ) demonstrated a significant extension of overall survival compared to conventional care regi ...

Results from a phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia ( AML ) aged 65 or older and ineligible f ...